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The primary technique for detecting the presence and monitoring the development of carotid 
atherosclerotic plaque is ultrasound. The development of ultrasound techniques has made it 
possible to precisely visualise not only blood flow, but also vessel walls, including atheroscle-
rotic plaque. Contrast-enhanced ultrasound examination enables one to make an objective 
observation of atherosclerotic plaque neovascularisation, clearly indicating active inflamma-
tion, which is an inherent feature of vulnerable (unstable) plaque. Depending on the exami-
nation method used, it is possible to precisely visualise different components of the plaque 
and its behaviour during blood flow through the vessel lumen or through the neovessels of 
the plaque, and, consequently, determine the possible presence of inflammation, which is a 
defining feature of plaque stability. The full utilisation of physical phenomena that underlie 
contrast-enhanced ultrasound will bring further enormous progress of diagnostic and prob-
ably also therapeutic methods for carotid atherosclerosis. The selection of the right examina-
tion method significantly accelerates diagnosis and adequate classification of plaque, and 
makes it possible to monitor the progression of atherosclerosis. However, one needs to bear 
in mind that ultrasound remains a very subjective method. The success of contrast-enhanced 
ultrasound also depends on the skills and experience of the examiner. Current attempts at 
increasing the objectivity of contrast-enhanced ultrasound examination using artificial intel-
ligence will make it possible in the future to make a definitive evaluation of atherosclerotic 














assessment of abnormalities in the precranial segments 
of carotid arteries. The development of ultrasound tech-
niques has made it possible to precisely visualise not only 
blood flow, but also vessel walls, including atherosclerotic 
plaque, which is a direct manifestation of the presence of 
atherosclerosis. The accuracy rate for precranial artery 
pathology diagnosis on ultrasound exceeds 90% according 
to literature data(2–6). In addition, high specificity of the pro-
cedure is emphasised.
The most significant difficulty when examining atheroscle-
rotic plaque lies in determining the potential point at which a 
stable atherosclerotic plaque transforms into an unstable one.
Introduction
The sheer number of methods currently used to image the 
precranial segments of carotid arteries (vessel walls, blood 
flow and atherosclerotic plaque itself) proves that it has 
not been possible yet to establish definitively which of them 
should be the gold standard for both determining the pres-
ence and assessing the severity of atherosclerosis, a disease 
that is one of the main causes of death and disability in 
Europe(1).
Over the last 20 years B-mode ultrasound combined with 
Doppler imaging has become the primary method of 
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Unstable plaque is described as the one which is a poten-
tial cause of brain ischaemia. It is characterised by a thin 
fibrous cap, increased proteoglycan content or increased 
number of calcifications and surface irregularities which 
lead to exposed endothelium. The image of atheroscle-
rotic plaque and preliminary assessment of its stability are 
described in the Gray-Weale–Nicolaides (GWN) classifica-
tion and its modified versions. GWN can serve as a poten-
tial assessment tool for further diagnostic investigation and 
treatment, and for therapy monitoring(7–11).
The course of atherosclerotic plaque development has not 
been fully discovered. However, it is believed that the “nat-
ural” development of atherosclerotic plaque is associated 
with repeated, alternate episodes of stabilisation and desta-
bilisation(12–14) (Fig. 1).
The majority of studies describing the mechanisms of 
atherosclerotic lesion progression focus on changes at 
the cellular level. These processes cause limited changes 
to the plaque’s structure leading to its local damage; 
in consequence, a cascade of destabilisation is trig-
gered(15,16). According to studies by Constantinides(17,18), 
the presence of neovascularisation in the lipid core of 
atherosclerotic plaque is a sign that the process lead-
ing to its impaired stability has been activated. It was 
also concluded(10,11,19,20) that changes in the structure of 
the lipid core of atherosclerotic plaque associated with 
impaired neovascularisation play a fundamental role in 
the transformation of the plaque’s collagen matrix, lead-
ing to core necrosis, and, subsequently, to loss of stability 
(Fig. 2).
Signs of active inflammation in the atherosclerotic plaque 
are assumed to be a definitive criterion of plaque instabil-
ity; these signs include lipid core neovascularisation(21,22) or 
products of plaque inflammation (C-reactive protein, inter-
leukin complexes, LDL oxidase, myeloperoxidase, glutathi-
one peroxidase etc.)(23,24).
A technique which makes it possible to visualise signs of 
atherosclerotic plaque instability in a very reliable manner 
is contrast-enhanced ultrasound (CEUS)(25–28).
It was discovered that bubbles filled with air or another 
gas (Fig. 3) are perfectly fit as a contrast agent for ultra-
sound examination, since they have a low volume, are 
stable, rheologically (haemodynamically) inactive and 
practically neutral for the body. This resulted in the 
development of contrast-enhanced blood flow examina-
tion techniques. Apart from investigating blood flow in 
large vessels (the aorta), medium (carotid arteries, aortic 
branches) and small ones (lobar and segmental arter-
ies, arcuate arteries of the kidneys, arteries of the circle 
of Willis), these techniques are used to examine blood 
flow in the capillaries. Capillary blood flow imaging 
has become of particular importance in the diagnosis 
of Raynaud’s disease (phenomenon), assessment of skin 
flap vitality for plastic surgery and even in microcircu-
lation imaging; in addition, capillary flow imaging is 
useful for the assessment of tumour and atherosclerotic 
plaque neovascularisation(25,26,29–36).
Ultrasound contrast agents modify acoustic impedance 
(acoustic rigidity) of tissues (the impedance of contrast 
agent microspheres is approximately 300 higher than that 
of red blood cells) and increase blood echogenicity. This 
phenomenon occurs as a result of changes in ultrasound 
wave parameters (extinction and attenuation) due to the 
presence of fine gas structures: ultrasound enhancing 
agent (UEA) microspheres.
Another characteristic of ultrasound enhancing agent 
microspheres, which is used to change blood echogenicity 
and increase or decrease the returning echoes, is the ability 
of microsphere walls to resonate in response to ultrasound 
waves with an appropriate frequency.
As a result of interaction between the microspheres and 
the ultrasound wave, their walls reach their resonant fre-
quency. As a result, apart from waves with fundamental fre-
quencies emitted by the ultrasound probe crystals, waves 
with harmonic frequencies also reach the receiver (ultra-
sound probe) (Fig. 4).
The probe also receives waves with subharmonic and 
ultraharmonic frequencies, which are used in differen-
tial tissue harmonic imaging (DTHI). Currently, the use 
of these kinds of waves is being investigated in clinical 
trials.
Fig. 2.  Atherosclerotic plaque with signs of neovascularisation: 
a diagram
Fig. 1.  A “natural history” of atherosclerotic plaque; Virmani–Burke 
(MRI)(12–14)
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UEA microspheres behave differently depending on 
the strength of the ultrasound beam expressed by the 
mechanical index (MI). This index reflects the probabil-
ity of unfavourable mechanical (non-thermal) bioeffects 
of ultrasounds associated with streaming and cavita-
tion effects. MI also shows the level of negative acoustic 
pressure in the ultrasound field, indicating the maximum 
amplitude of a pressure pulse in a tissue subjected to 
ultrasounds.
At a low MI (<0.4), the response of the microspheres is lin-
ear: oscillation induced by ultrasounds, which is caused by 
the compression and decompression of microsphere walls, 
does not cause their damage or resonance (Fig. 6).
At an intermediate MI (0.4–0.8), there is a non-linear 
response associated with microsphere wall resonance 
(Fig. 7).
At a high MI (>0.8), microsphere walls are damaged, 
which emits a high-intensity signal. Appropriate acquisi-
tion requires intermittent imaging: time is needed for sub-
sequent bubbles to flow into the vessel lumen and into the 
probe field, where they will be ruptured by the emitted 
ultrasounds (Fig. 8).
The continuous development of contrast-enhanced ultra-
sound techniques has been generating new diagnostic and 
therapeutic possibilities every day.
In 2014, a comprehensive paper was developed sum-
marising exclusively intravascular phenomena in which 
UEA microspheres are used(36,37). Currently, in studies on 
nanodroplets, methods of extravascular – interstitial – use 
of UEA for the diagnosis and therapy of atherosclerotic 
plaque are also developed(38,39).
Decision to use ultrasound enhancing agents 
to investigate atherosclerotic plaque stability
In a situation where ultrasound examination of carotid 
arteries reveals the presence of a potentially unstable 
plaque, meeting instability criteria, and the patient has a 
history of cerebrovascular accident (CVA) with no clear 
aetiology, a CEUS examination is warranted to detect 
Another phenomenon utilised in contrast-enhanced ultra-
sound imaging is pulse inversion, which consists in emit-
ting two pulses one immediately after another with the 
same amplitude, but a shifted phase. Since microspheres 
are “non-linear reflectors” of ultrasounds, the echos gen-
erated by them do not overlap, as is the case for echoes 
generated by tissues, but enhance one another. Ultrasound 
examination techniques utilise the phenomenon of overlap-
ping wave harmonics (Fig. 4).
These phenomena and the possibility of maintaining the 
integrity of the microbubble wall or inducing its controlled 
rupture allow one to use ultrasound enhancing agents in 
multiple ways to examine atherosclerotic plaques located 
in carotid artery walls (Fig. 5).
Fig. 3.  Electron microscopic image of SonoVue microbubbles
Fig. 4.  Image of resonant frequency wave reception during the pro-
cedure (diy.audio.pl)
Fig. 5.  A diagram of mutual interaction between ultrasounds and 
microspheres
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possible plaque neovascularisation, which is practically a 
definitive sign of plaque instability (Fig. 9).
A contrast-enhanced ultrasound examination is not a uni-
directional procedure. The type of data acquired changes 
depending on the contrast agent used, manner of its admin-
istration and method of observation.
Ultrasound examination using UEA has a limited 
spatial and temporal scope considering the manner 
of administration and the method of acquisition and 
observation. Therefore, after the patient’s eligibility 
for the procedure has been determined, a precise algo-
rithm of action should be established, which includes 
the selection of:
• UEA,
• UEA manner of administration,
• phase of observation of UEA propagation in the vessel 
and tissues,
• method of UEA interaction with the ultrasound system,
• mode of procedure recording,
• method of assessment of examination findings.
Ultrasound system
An ultrasound system equipped with contrast-enhanced 
examination option is necessary. This option usually 
has one or two timers displaying the length of the loop 
recorded during the procedure. For this option, the sys-
tem itself should include the possibility to record a film 
as raw data with a length covering at least the follow-
ing phases: wash-in, arterial, venous and wash-out. The 
systems available on the market enable one to acquire a 
few loops, including their combined record. The contrast 
option should also include flash mode, which makes it 
possible to use the pulse inversion method. This method 
involves the emission of two ultrasound pulses with the 
same amplitude, shifted by 180° between one another, at 
a very short interval. This method utilises a non-linear 
response of UEA microspheres: overlapping echoes of 
fundamental wave harmonics. It is also necessary to 
have an indication of the mechanical index displayed on 
the desktop.
The standard options of systems supporting the use of 
ultrasound enhancing agents include the colour flow 
mode (CFM) and power Doppler (PD) or its modification: 
directional power Doppler (DPD). Power Doppler options 
(PD, DPD) are necessary for possible microsphere rup-
turing using the flash or replenish method. A PD pulse 
necessary for the flash method is released automatically 
by the ultrasound system at preset moments or delivered 
on demand by the examiner after they press an appropri-
ate function key.
An appropriate ultrasound probe is necessary to conduct 
contrast-enhanced examination of atherosclerotic plaque. 
Carotid atherosclerotic plaques are usually examined using 
vascular probes with a foot print of approximately 45 mm, 
frequency range of 3–11 MHz and nominal frequencies of 
5–8 MHz.
Studies are also conducted on the use of a linear high speed 
volumetric imaging probe with UEA for three-dimensional 
imaging of the surface of atherosclerotic plaque(37,40,41).
Which contrast agent to use?
Based on pharmacokinetic properties, ultrasound enhanc-
ing agents are divided into those which:
• do not pass through the pulmonary vascular bed (only 
the right ventricle of the heart is visualised; short-term 
action): Echovist;
• pass through the pulmonary vascular bed, have a short 
half-life (less than 5 minutes from intravenous admin-
istration), produce a low signal on harmonic imaging 
when low acoustic power is used: Albunex, Levovist;
• pass through the pulmonary vascular bed, have a long 
half-life (over 5 minutes from intravenous administra-
tion), produce a high signal on harmonic imaging when 
Fig. 6.  MI <0.4; microsphere oscillation
Fig. 7.  Intermediate MI of 0.4–0.8; microsphere resonance
Fig. 8.  MI >0.8; microsphere wall rupture
Fig. 9.  Type (class) I atherosclerotic plaque, not visible on B-mo-
de imaging, diagnosed using superb microvascular imaging 
(SMI) (present authors’ material)
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preset time, which is usually 100 msec in the case of flash 
mode, and remain visible for a few seconds as a result of 
physical properties of the display monitor(34) (Fig. 10).
2. Venous phase (up to 60–90 sec from the administra-
tion of contrast agent) makes it possible to visualise 
the increasing contrast enhancement of the image of 
plaque neovessels with the effect of excessive enhance-
ment: UEA “flowing out” of the vessels, which is 
described as a “blooming effect” (Fig. 11).
The arterial and venous phases are assessed as wash-in 
phases.
3. Microcirculation phase (90–180 sec from UEA admin-
istration) is a phase of continued contrast enhance-
ment with excessive UEA being washed out of the 
Region of Interest (ROI). 
In this phase, atherosclerotic plaque neovessels are filled 
with blood and their echo is enhanced directly by undam-
aged UEA microspheres or by an increased extinction 
caused by gas particles (following microbubble rupture). 
Depending on the method used, the microspheres and gas 
remaining after microbubble rupture are washed out of the 
lumen of large blood vessels, which enables one to perform 
thorough observation and possible measurement of plaque 
enhancement (Fig. 12).
4. Late phase (over 180 sec after contrast agent adminis-
tration): UEA wash-out from plaque vessels. 
In this phase, distinctly hypoechoic elements can be 
observed, which are impossible to distinguish from the ves-
sel lumen under physiological conditions. These include jux-
taluminal black areas (JBA): extremely hypoechoic areas, 
described as lesions with an echogenicity of <25 GSM 
(grey-scale median) units, with no fibrous cap, histologi-
cally defined as necrotic components or fragments of lipid 
core of a damaged plaque or interpreted as GWN type I 
plaque described as thin-cap atheromatic plaque (TCAP), 
impossible to visualise clearly on B-mode ultrasound, and 
mobile components (described as “jellyfish sign”, with an 
image consistent with JBA, subject to displacement during 
heartbeat). The mobility of these areas can also be described 
low acoustic power is used: Echogen, Optison, SonoVue, 
Sonovist;
• are captured in the liver and spleen, make imaging 
possible after the vascular phase: Levovist, Sonovist, 
Sonazoid.
Currently, in Poland, two ultrasound enhancing agents are 
approved for use. SonoVue, a Bracco product, contains sul-
phur hexafluoride and phospholipid stabilisers. It is a con-
trast agent that can be used to examine peripheral vessels. 
Sulphur hexafluoride (also called elegas, SF6-enflurane) is 
an inorganic chemical compound with very good dielectric 
properties. It does not have any colour, taste or odour and 
is approximately 6 times heavier than air. Sulphur hexaflu-
oride is a non-flammable gas with a low chemical activity, 
which is non-toxic under normal conditions (comparable to 
noble gases such as argon or helium). It is only at very high 
temperatures (>200°C, e.g. at electric arc temperature) and 
at the presence of humidity or oxygen that small amounts 
of toxic substances can occur, mainly sulphur tetrafluoride 
(SF4) and thionyl fluoride (SOF2).
Enhancing agent microspheres are ruptured with ultra-
sounds; fine bubbles of gas can circulate freely in the blood-
stream. Larger amounts are exhaled and the lipid “shells” 
are metabolised in the liver and subsequently excreted with 
bile.
Another UEA is Optison (General Electric), which is cur-
rently approved for the Polish market, but only for cardiac 
ultrasound scans. 
Ultrasound enhancing agents are tolerated very well: the 
reported anaphylactic reactions following their administra-
tion are estimated to occur in 0.001% of cases. No kidney 
toxicity has been found. UEA half-life is approximately 12 
minutes.
The amount of UEA administered during the procedure 
depends on the method and the result analysis protocol 
used.
Observation phase for ultrasound enhancing 
agent (UEA) propagation in the vessel lumen
1. Arterial phase (up to 30–45 sec from the administra-
tion of contrast agent) makes it possible to assess the 
vessel lumen/atherosclerotic plaque boundary due to 
precise contouring of the observed object. 
The assessment of the lumen/plaque boundary can be dif-
ficult on a scan using the classic algorithm with UEA bolus 
as a result of microspheres filling the vessel lumen in excess. 
This boundary is best visible when the temporal maximum 
intensity projection (TMIP) technique is used (transient and 
flash methods). In TMIP, every microsphere, after becom-
ing resonant following a power Doppler pulse, leaves its 
own separate trace of motion, reproduced by subsequent 
microbubbles entering the field of a probe set to flash mode. 
Authors(38,39,42) explain this as an “open shutter” image, where 
subsequent traces of microsphere motion are tracked for a 
Fig. 10.  CEUS, arterial phase, vessel lumen filling: well visible ves-
sel lumen–plaque boundary; red arrow – plaque neovessel; 
yellow arrow – mechanical index value (present authors’ 
own material)
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as “intraplaque contents” (IC) or “motion of intraplaque con-
tents” (MIC)(43,44), i.e. mobility of areas referred to as JBA 
that is independent from the heartbeat. Here, it should be 
noted that MIC interferes with the image of subjective con-
trast enhancement of an unstable plaque(44) (Fig. 13).
The microcirculation and late phases are referred to as the 
wash-out phase.
Which contrast agent administration 
technique to use?
The selection of the contrast agent administration tech-
nique depends on the structure of the examined object 
and on the aspect for which observation has been planned. 
Therefore, it needs to be decided whether atherosclerotic 
plaque itself, the boundary between the vessel lumen and 
plaque or plaque vascularisation will be observed. Thus, 
the contrast agent administration technique should be 
selected with a view to its most effective use.
The currently used methods allow one to make complex 
observations provided that the advantages and possibilities 
of the contrast agent are used properly. Combinations of 
the methods described below are used to examine carotid 
atherosclerotic plaques.
1. Classic method: the contrast agent is administered as a 
bolus, with saline washing. A low MI value (up to 0.4) 
should be set in the ultrasound system.
During the procedure, the contrast agent is used as a modi-
fier of tissue impedance: with a low mechanical index of 
the sound wave, the microspheres are not ruptured (the 
microbubbles pass through the vessels that are large 
enough). During the procedure, it is possible to observe 
echoes appearing in the atherosclerotic plaque’s topogra-
phy, consistent with wash-in and wash-out phases.
This method allows one to determine the presence of 
vessels in the observed atherosclerotic plaque. Due to a 
low image resolution, relatively wide vessels and a small 
amount of the contrast agent entering a neovascularised 
plaque are visualised. In this method, it is only possible 
to make a subjective evaluation and observe potentially 
contrast-enhanced atherosclerotic plaque components 
(Fig. 14). The amount of UEA administered is from a mini-
mum of 4 ml (Clevert) up to 8 ml (Feinstein).
2. Modified classic method: the contrast agent is admin-
istered in fractions. 
Half of a single dose should be administered in a bolus, 
then saline washing is performed, and subsequently the 
remaining portion of the contrast agent is administered. 
A low MI value (up to 0.5) should be set in the system. This 
method makes it possible for contrast agent microspheres 
to stay longer in the neovascularised plaque. However, the 
assessment of the wash-out phase is not possible (Fig. 15). 
The total amount of UEA is 8 ml administered in fractions 
(as described above).
3. Transient method: the contrast agent is administered as 
a bolus, with saline washing. 
It is necessary to set the mechanical index in the ultra-
sound system to high values: MI >1.2(31) (0.8 according to 
other authors)(45). This method makes it possible to rupture 
the microspheres immediately after they reach the region 
of interest. During the procedure, due to the distinctly 
Fig. 11.  Badanie CEUS – faza żylna, wypełnienie światła naczynia 
– zatarta granica światło naczynia–blaszka; strzałka niebie-
ska – wartość MI, strzałka biała – obszar badanej blaszki 
(materiał własny)
Fig. 12.  CEUS: microcirculation phase. Obliterated vessel lumen–
plaque boundary; black arrow – plaque area under examina-
tion, red arrow – MI value (present authors’ own material)
Fig. 13.  Late phase, replenish mode, black arrow – plaque–vessel 
wall boundary, blue arrow – plaque–vessel lumen bounda-
ry, red arrow – MI value (present authors’ own material)
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values on ultrasound (the adventitia is GSM 180–200)(47). 
The assessment of enhancement in the arterial phase and 
the wash-out phase is made using the so-called long loop: 
observation lasting at least 240 sec. The difference of at least 
20 GSM units between plaque enhancement before and after 
contrast agent administration is considered significant. The 
amount of UEA administered is a minimum of 8 ml (Burns).
Evaluation of atherosclerotic plaque 
neovascularisation
In the studies published to date, CEUS examination 
of atherosclerotic plaques was analysed based on vari-
ous protocols. The simplest method of atherosclerotic 
plaque neovessel filling assessment is the observation 
of loops recorded during the procedure, which was 
proposed by Feinstein(26). The most common protocol, 
which is recommended by Iezzi et al.(26,27), is that involv-
ing a dynamic examination. It consists in observing ROI 
increased extinction of the medium, the plaque/vessel lumen 
boundary can be assessed more precisely. This method partly 
utilises the TMIP phenomenon (Fig. 16). The amount of UEA 
administered is a minimum of 4 ml.
4. Replenish mode, flash mode: the contrast agent is 
administered in a slow infusion, with subsequent saline 
washing. 
It is necessary to set the mechanical index to a low value 
(MI <0.4). Once the vessel is filled with the contrast agent, 
the replenish mode, a colour Doppler function is used 
(Fig. 17). This method makes it possible to rupture the 
microspheres in a controlled manner to release gas in order 
to thoroughly fill the lumen of not only carotid arteries, but 
also that of atherosclerotic plaque neovessels. This method 
utilises the TMIP phenomenon. The examination findings 
can be evaluated using GSM analysis(46). GSM presents the 
median of the pixel tonal distribution frequency in the range 
of 0 (black tones) to 256 (white tones). On ultrasound, fluid 
corresponds to the lowest values (blood is GSM 0–5). Solid 
tissues, on the other hand, correspond to the highest GSM 
Fig. 14.  CEUS using the classic method: visible contrast agent mi-
crosphere echoes in atherosclerotic plaque’s topography 
on the posterior wall of the vessel; black arrow – image of 
plaque with UEA echoes, red arrow – MI value (present au-
thors’ own material)
Fig. 15.  CEUS using the modified classic method; red arrows – 
atherosclerotic plaque, blue arrow – time of contrast agent 
administration, yellow arrow – MI value (present authors’ 
own material)
Fig. 16.  CEUS using the transient method: visible echoes of the con-
trast agent in atherosclerotic plaque’s topography on the 
posterior wall of the vessel, GWN type (class) III circular 
plaque. A. Time: 33 sec from administration. B. Time: 111 sec 
from UEA administration; black arrow – plaque area with 
contrast agent echoes, blue arrow – image of the method, 
red arrow – MI (present authors’ own material)
A
B
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enhancement during the procedure, in the wash-in and 
wash-out phases. This protocol includes the late phase, 
recorded at 6 minutes from contrast agent administra-
tion after applying flash mode and rupturing contrast 
agent microbubbles using a power Doppler pulse. This 
protocol requires continuous recording of the procedure 
based on the CEUS programme timer assigned to a set-
ting in the ultrasound system.
A protocol with a late wash-out phase, with UEA wash-out 
curve being recorded, makes it possible to observe neoves-
sels while avoiding blooming artefacts in microspheres 
washed out of the arteries.
A similar protocol was used in studies by Clevert et al. and 
Coli et al.(25,30), in which, apart from subjective evaluation, 
a full examination record consisting of a 280–360-second 
loop was analysed. 
According to the present authors, the examination proto-
col proposed by Hoogi(48), among others, which includes a 
repeated assessment of plaque enhancement in ROI, seems to 
provide a precise account of the level of atherosclerotic plaque 
vascularisation during the procedure, slightly reducing the role 
of subjective evaluation for the benefit of objective assessment, 
with off-line enhancement analysis using GSM (Fig. 18).
Another method of increasing the assessment objectivity is 
the scoring system proposed by Akkus(49,50) to evaluate the 
enhancement of the atherosclerotic plaque in the predicted 
arterial, venous and interstitial phases using GSM analysis.
Conclusion
The ultrasound image of atherosclerotic plaque allows 
one to draw conclusions regarding its future fate, and, 
most importantly, make decisions on further patient 
management.
However, this is possible on condition that the findings are 




Fig. 17.  CEUS using the TMIP method, replenish-flash mode: visi-
ble echoes of the contrast agent in atherosclerotic plaque’s 
topography on the posterior wall of the vessel, GWN type 
(class) I plaque. A. Before PD pulse. B. During the pulse. 
C. After PD pulse; white arrow – atherosclerotic plaque 
with contrast agent echoes; red arrow – MI value during 
the scan; blue arrow – indication of the method (present 
authors’ own material)
Fig. 18.  Evaluation of the change of plaque enhancement with the 
contrast agent on GSM analysis. Red arrow – ROI, yellow 
and blue arrows – GSM values (present authors’ own ma-
terial)
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beyond doubt, which is an inherent feature of unstable (vul-
nerable) plaque. Current attempts at making CEUS more 
objective with the help of artificial intelligence (AI) will 
make it possible in the future to make a definitive assess-
ment of plaque stability, and, consequently, evaluate the 
risk of CVA adequately.
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clinical situation has been made and the patient has been 
adequately assigned to a prognostic group. Considering 
the fact that atherosclerosis is a changeable, progressive 
process with atherosclerotic plaque transforming dynami-
cally from a stable to an unstable state, one should make a 
very cautious evaluation of the current disease process and 
the potential or actual complications. This is because ultra-
sound examination is a highly subjective procedure whose 
result depends to a large extent on the experience of the 
examiner and the quality of the equipment used. Contrast-
enhanced ultrasound allows one to determine the pres-
ence of neovascularisation in an objective manner; thus, 
the presence of active inflammation can be demonstrated 
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